Literature DB >> 24055150

Susceptibility profile of a Brazilian yeast stock collection of Candida species isolated from subjects with Candida-associated denture stomatitis with or without diabetes.

Paula Volpato Sanitá1, Ewerton Garcia de Oliveira Mima, Ana Cláudia Pavarina, Janaina Habib Jorge, Ana Lúcia Machado, Carlos Eduardo Vergani.   

Abstract

OBJECTIVE: This study investigated the susceptibility of 198 clinical isolates of Candida species against caspofungin, amphotericin B, itraconazole, and fluconazole. STUDY
DESIGN: Suspensions of the microorganisms were spread on Roswell Park Memorial Institute (RPMI) agar plates. Etest strips were placed on the plates, and the minimal inhibitory concentration (MIC) was read after incubation (48 h at 37 °C). Data were analyzed by a factorial analysis of variance and a 2 × 2 post hoc test (α = .05).
RESULTS: C glabrata showed the highest MIC values (P < .001) against caspofungin, itraconazole, and fluconazole. For amphotericin B, the MIC values of C tropicalis and C glabrata (P = .0521) were higher than those of C albicans (P < .001). Itraconazole was the least effective antifungal; 93.3% of the C glabrata isolates, 3.3% of the C albicans, and 1.3% of the C tropicalis were resistant. All microorganisms were susceptible to caspofungin and amphotericin B.
CONCLUSIONS: Caspofungin and amphotericin B should be recommended as an effective alternative for the management of oral Candida infections when treatment with topical or other systemic drugs has definitely failed.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24055150     DOI: 10.1016/j.oooo.2013.07.002

Source DB:  PubMed          Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol


  7 in total

1.  Prevalence and Antifungal Susceptibility Profile of Oral Candida spp. Isolates from a Hospital in Slovakia.

Authors:  Lucia Černáková; Anna Líšková; Libuša Lengyelová; Célia F Rodrigues
Journal:  Medicina (Kaunas)       Date:  2022-04-22       Impact factor: 2.948

2.  Antifungal Susceptibility Testing with Etest for Candida Species Isolated from Patients with Oral Candidiasis.

Authors:  You Bum Song; Moo Kyu Suh; Gyoung Yim Ha; Heesoo Kim
Journal:  Ann Dermatol       Date:  2015-12-07       Impact factor: 1.444

3.  Characterization of a novel antibiofilm effect of nitric oxide-releasing aspirin (NCX-4040) on Candida albicans isolates from denture stomatitis patients.

Authors:  Francisco Madariaga-Venegas; Roberto Fernández-Soto; Luisa Fernanda Duarte; Nicole Suarez; Daniela Delgadillo; José A Jara; Ricardo Fernández-Ramires; Blanca Urzúa; Alfredo Molina-Berríos
Journal:  PLoS One       Date:  2017-05-11       Impact factor: 3.240

4.  Antifungal Drug Susceptibility of Candida Species Isolated from HIV-Positive Patients Recruited at a Public Hospital in São Luís, Maranhão, Brazil.

Authors:  Ana L G Terças; Sirlei G Marques; Eduardo B Moffa; Márcia B Alves; Conceição M P S de Azevedo; Walter L Siqueira; Cristina A Monteiro
Journal:  Front Microbiol       Date:  2017-03-02       Impact factor: 5.640

5.  In Vitro Antifungal Susceptibility of Candida Species Isolated from Iranian Patients with Denture Stomatitis.

Authors:  Saeid Mahdavi Omran; Maryam Rezaei Dastjerdi; Maryam Zuashkiani; Vahid Moqarabzadeh; Mojtaba Taghizadeh-Armaki
Journal:  Biomed Res Int       Date:  2018-05-16       Impact factor: 3.411

6.  Effects of Storage Temperature and pH on the Antifungal Effects of Commercial Oral Moisturizers against Candida Albicans and Candida Glabrata.

Authors:  Mamoru Murakami; Kae Harada; Yasuhiro Nishi; Takaharu Shimizu; Sara Motoyama; Masahiro Nishimura
Journal:  Medicina (Kaunas)       Date:  2020-10-07       Impact factor: 2.430

7.  Frequency of clinically isolated strains of oral Candida species at Kagoshima University Hospital, Japan, and their susceptibility to antifungal drugs in 2006-2007 and 2012-2013.

Authors:  Yoshiaki Kamikawa; Youichirou Mori; Tomohiro Nagayama; Junichi Fujisaki; Daisuke Hirabayashi; Ryoichi Sakamoto; Tomofumi Hamada; Kazumasa Sugihara
Journal:  BMC Oral Health       Date:  2014-02-20       Impact factor: 2.757

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.